ZHEJIANG STARRY PHARMACEUTICAL CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.87 CNY | +0.17% |
|
+9.00% | -15.70% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Zhejiang Starry Pharmaceutical Co., Ltd. is principally engaged in the research and development (R&D), production and sales of X-ray contrast medium, quinolone antimicrobial agents and other drugs' pharmaceutical raw materials and intermediates. The X-ray contrast medium's major product is iohexol active pharmaceutical ingredient. Quinolone antimicrobial agents' major products are levofloxacin hydrochloride active pharmaceutical ingredient and levofloxacin hemihydrates active pharmaceutical ingredient.
Sector
Pharmaceuticals
Calendar
2024-04-29
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
11.87
Average target price
-
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -15.70% | 561M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- 603520 Stock
- News Zhejiang Starry Pharmaceutical Co.,Ltd.
- Zhejiang Starry Pharma’s CFO Resigns
